Personalis(US:PSNL)2026-02-26 21:11Revenue Performance - Total revenue for 2025 was $69.6 million, a decrease of 18% or $15.0 million compared to 2024, primarily due to lower revenue from Enterprise sales, which dropped to $5.9 million from $25.4 million[344]. - Revenue from population sequencing increased by $4.3 million, or 58%, contributing positively to overall revenue despite the decline in Enterprise sales[344]. - Clinical test revenue reached $2.0 million, more than double the $0.8 million reported in 2024, indicating strong clinical momentum[346]. - Clinical test volume increased to 16,233 tests, a nearly 400% rise from 3,285 tests in 2024, reflecting significant growth in testing services[346]. - Total revenue for 2025 was $69.648 million, a decrease of 18% from $84.614 million in 2024[364]. - Revenue from pharma testing services decreased by 4% to $48.661 million, primarily due to a reduction in clinical trial samples processed for Moderna[364]. - Enterprise sales revenue dropped significantly by 77% to $5.885 million, attributed to the expiration of minimum volume commitments with Natera[366]. - Population sequencing revenue increased by 58% to $11.766 million, driven by a higher number of samples processed[364]. - Clinical diagnostic revenue surged by 166% to $2.018 million, supported by new Medicare coverage determinations for NeXT Dx and NeXT Personal Dx[368]. Financial Position - The company ended the year with approximately $240.0 million in cash, cash equivalents, and short-term investments, including $109.0 million from its At-The-Market sales program[346]. - Cash and cash equivalents, along with short-term investments, totaled $239.953 million as of December 31, 2025, up from $185.009 million in 2024[380]. - Total stockholders' equity increased to $261.185 million in 2025, compared to $202.957 million in 2024[361]. - As of December 31, 2025, the company had approximately $240.0 million in cash and cash equivalents and short-term investments to fund material cash requirements[387]. - The company reported a $96.7 million increase in net proceeds from sales of common stock under its ATM facility in 2025[386]. - The company plans to fund its material cash requirements through existing cash, anticipated cash receipts, and may seek additional equity or debt financing if necessary[387]. - The company has an outstanding noninterest bearing loan of $2.1 million, with $1.2 million paid in January 2026 and $0.9 million payable in 2027[391]. - The company’s short-term investments portfolio is primarily invested in highly rated securities to minimize principal loss risk[383]. - The company’s noncancelable operating lease payments were $62.4 million as of December 31, 2025[391]. Operational Highlights - Medicare coverage was secured for breast cancer recurrence surveillance and Stage I to III NSCLC, expected to drive clinical revenue and market share growth in the MRD space[345]. - Approximately 571,000 human samples have been sequenced to date, with 219,000 being whole human genomes, showcasing the company's capacity in genomic testing[343]. - The company has expanded its collaboration with Tempus to market NeXT Personal Dx for colorectal cancer, extending the agreement through November 25, 2029[342]. - The company is focusing on three key indications: breast cancer, lung cancer, and immunotherapy monitoring, supported by collaborations with leading cancer centers and research institutions[341]. - The company is pioneering the ultrasensitive MRD testing market, which is expected to lead to earlier interventions and improved patient outcomes[346]. Cost and Expenditure - Total costs and expenses rose by 3% to $157.705 million, with selling, general and administrative expenses increasing by 16%[370]. - Interest income increased by 30% to $7.155 million, while interest expense rose significantly by 754% to $205 thousand[377]. - The net loss for 2025 was $81.270 million, compared to a net loss of $81.284 million in 2024[361]. - Net cash used in operating activities increased to $(74.9) million in 2025 from $(45.2) million in 2024, primarily due to working capital needs and lower revenue[384]. - Operating expenditures are expected to increase compared to 2025 levels to support the growth of clinical diagnostic offerings[389]. - The company expects capital expenditures to be between $8 million to $10 million in 2026 and between $10 million to $12 million in each of the years 2027 and 2028[390].